NCT06462001View on ClinicalTrials.gov

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Transitional Cell CarcinomaTransurethral Resection
Interventions
BIOLOGICAL

Bacillus Calmette-Guerin Vaccine Intravesical

BCG (Oncotice) is administered intravesically as per usual standard of care

DRUG

Mitomycin

MMC is administered intravesically as per usual standard of care

Trial Locations (1)

NG51PB

Nottingham University Hospitals, Nottingham

All Listed Sponsors
collaborator

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OTHER

collaborator

University of Sydney

OTHER

lead

Nottingham University Hospitals NHS Trust

OTHER